TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.


Options:
A: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate
B: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
D: Arm Label: Anti-TNFa regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: Anti IL12/23 regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Cyclosporine regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclosporine | Arm Label: anti-interleukin 17 A regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Arm Label: inhibitor of phosphodiesterase-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Anti-TNFa regimen | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Anti IL12/23 regimen | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): Cyclosporine regimen | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): anti-interleukin 17 A regimen | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): inhibitor of phosphodiesterase-4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.


Options:
A: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
B: Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 70 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 70 mg SC | Arm Label: 280 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 280 mg SC | Arm Label: 210 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg SC | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 70 mg SC; Assigned to Arm(s): 70 mg SC | Intervention Type: DRUG; Name: 210 mg SC; Assigned to Arm(s): 210 mg SC | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC | Intervention Type: DRUG; Name: 280 mg SC; Assigned to Arm(s): 280 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
D: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.


Options:
A: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
B: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.


Options:
A: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
B: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A
D: Arm Label: 1 mg PF-03049423; Type: EXPERIMENTAL; Interventions: Drug: PF-03049423 | Arm Label: 3 mg of PF-03049423; Type: EXPERIMENTAL; Interventions: Drug: PF-03049423 | Arm Label: 6 mg of PF-03049423; Type: EXPERIMENTAL; Interventions: Drug: PF-03049423 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: PF-03049423; Assigned to Arm(s): 1 mg PF-03049423 | Intervention Type: DRUG; Name: PF-03049423; Assigned to Arm(s): 3 mg of PF-03049423 | Intervention Type: DRUG; Name: PF-03049423; Assigned to Arm(s): 6 mg of PF-03049423 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Atorvastatin on the NO-system in Patients With Type 2 Diabetes and Nephropathy
Brief Summary: It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood. Nitric oxide (NO) production is reduced in several chronic diseases such as nephropathy, diabetes and hypertension. The purpose of this study is to investigate the effect of Atorvastatin treatment on the NO-system measuring renal and cardiovascular variables in patients with type 2 diabetes with nephropathy.


Options:
A: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin, Placebo
C: Arm Label: standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard therapy | Arm Label: fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): fluvastatin | Intervention Type: DRUG; Name: standard therapy; Assigned to Arm(s): standard therapy
D: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Unikalk | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Unikalk; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Metformin on the Ovarian Response to Gonadotropins for in Vitro Fertilization Treatment in Patients With Polycystic Ovary Syndrome and Predictors of Poor Ovarian Response
Brief Summary: Metformin should be administered with caution and could be potentially dangerous in infertile patients with PCOS who show a poor ovarian response and are undergoing gonadotropin-based ovarian stimulation. However, data that address this point are totally lacking.

On the basis of these considerations, the aim of the current clinical trial was to test the hypothesis that metformin reduces the ovarian response in infertile patients with PCOS who have a potentially poor ovarian response and who undergo gonadotropin stimulation for IVF cycles.


Options:
A: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Metformin-treated group; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin-treated group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Metformin on the Ovarian Response to Gonadotropins for in Vitro Fertilization Treatment in Patients With Polycystic Ovary Syndrome and Predictors of Poor Ovarian Response
Brief Summary: Metformin should be administered with caution and could be potentially dangerous in infertile patients with PCOS who show a poor ovarian response and are undergoing gonadotropin-based ovarian stimulation. However, data that address this point are totally lacking.

On the basis of these considerations, the aim of the current clinical trial was to test the hypothesis that metformin reduces the ovarian response in infertile patients with PCOS who have a potentially poor ovarian response and who undergo gonadotropin stimulation for IVF cycles.


Options:
A: Intervention Type: DRUG; Name: metformin XR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): N/A
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients
Brief Summary: The purpose of this study is to investigate whether the anabolic potentials of insulin may be used to reverse the catabolic effects of hemodialysis in non-diabetic patients with end-stage renal failure.


Options:
A: Arm Label: BI 1356; Type: ACTIVE_COMPARATOR; Interventions: Drug: BI 1356 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Glukose-infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucose-infusion | Arm Label: Glucose-insulin infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucose-insulin infusion | Intervention Type: DRUG; Name: Glucose-infusion; Assigned to Arm(s): Glukose-infusion | Intervention Type: DRUG; Name: Glucose-insulin infusion; Assigned to Arm(s): Glucose-insulin infusion
C: Arm Label: Saxa; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Insulin degludec (IDeg); Type: EXPERIMENTAL; Interventions: Drug: insulin degludec | Arm Label: Insulin glargine (IGlar); Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): Insulin degludec (IDeg) | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): Insulin glargine (IGlar)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Intensive Exercise Training Compared to Inactive Controls on Coronary Collateral Circulation and Plaque Composition in Patients With Significant Stable Coronary Artery Disease
Brief Summary: Exercise training in patients with coronary artery disease is able to correct several risk factors. Furthermore endothelial function can be improved.

There are some hinds for improved collateral circulation after exercise training, nevertheless there is no study showing significant improvement/ increase in coronary collaterals. This might be due to technique of collateral measurement. Therefore we conduct a study were coronary blod flow before and after 4 weeks of exercise training were measured.


Options:
A: Arm Label: PBL- patient education; Type: EXPERIMENTAL; Interventions: Behavioral: PBL in patient education, Behavioral: Mailed patient information | Arm Label: Mailed patient information; Type: EXPERIMENTAL; Interventions: Behavioral: Mailed patient information | Intervention Type: BEHAVIORAL; Name: PBL in patient education; Assigned to Arm(s): PBL- patient education | Intervention Type: BEHAVIORAL; Name: Mailed patient information; Assigned to Arm(s): Mailed patient information, PBL- patient education
B: Arm Label: STANDARD OF CARE; Type: OTHER; Interventions: Other: standard of care | Arm Label: PHYSICAL ACTIVITY INTERVENTION; Type: EXPERIMENTAL; Interventions: Other: physical activity intervention | Intervention Type: OTHER; Name: physical activity intervention; Assigned to Arm(s): PHYSICAL ACTIVITY INTERVENTION | Intervention Type: OTHER; Name: standard of care; Assigned to Arm(s): STANDARD OF CARE
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: intensive exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive exercise training | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): Exercise training | Intervention Type: BEHAVIORAL; Name: Intensive exercise training; Assigned to Arm(s): intensive exercise training
D: Arm Label: AB sequence; Type: EXPERIMENTAL; Interventions: Other: Usual care followed by the use of HeartHab application | Arm Label: BA sequence; Type: EXPERIMENTAL; Interventions: Other: Use of HeartHab application followed by usual care | Intervention Type: OTHER; Name: Use of HeartHab application followed by usual care; Assigned to Arm(s): BA sequence | Intervention Type: OTHER; Name: Usual care followed by the use of HeartHab application; Assigned to Arm(s): AB sequence

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Intensive Exercise Training Compared to Inactive Controls on Coronary Collateral Circulation and Plaque Composition in Patients With Significant Stable Coronary Artery Disease
Brief Summary: Exercise training in patients with coronary artery disease is able to correct several risk factors. Furthermore endothelial function can be improved.

There are some hinds for improved collateral circulation after exercise training, nevertheless there is no study showing significant improvement/ increase in coronary collaterals. This might be due to technique of collateral measurement. Therefore we conduct a study were coronary blod flow before and after 4 weeks of exercise training were measured.


Options:
A: Arm Label: Weight Loss; Type: EXPERIMENTAL; Interventions: Other: Weight Loss | Arm Label: Interval Training; Type: EXPERIMENTAL; Interventions: Other: Interval Training | Intervention Type: OTHER; Name: Interval Training; Assigned to Arm(s): Interval Training | Intervention Type: OTHER; Name: Weight Loss; Assigned to Arm(s): Weight Loss
B: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: intensive exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive exercise training | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): Exercise training | Intervention Type: BEHAVIORAL; Name: Intensive exercise training; Assigned to Arm(s): intensive exercise training
D: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Study Examining the Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-Assisted Laparoscopic Radical Prostatectomy
Brief Summary: To date, there is a lack of consensus concerning the optimal timing for removal of the urethral catheter, its related complications, the effectiveness in prophylactic drug use to reduce complication, and the patient reported outcomes (quality of life) after robot-assisted laparoscopic prostatectomy (RALP). The purpose of this study is to determine the impact of tamsulosin on voiding patterns following early urethral catheter removal after RALP for prostate cancer.


Options:
A: Arm Label: Early removal group; Type: EXPERIMENTAL; Interventions: Procedure: Early removal group | Arm Label: Normal removal group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Normal removal group | Intervention Type: PROCEDURE; Name: Early removal group; Assigned to Arm(s): Early removal group | Intervention Type: PROCEDURE; Name: Normal removal group; Assigned to Arm(s): Normal removal group
B: Arm Label: Foley; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Foley; Type: ACTIVE_COMPARATOR; Interventions: Other: No Foley | Intervention Type: OTHER; Name: No Foley; Assigned to Arm(s): No Foley
C: Arm Label: Group A (treatment group); Type: EXPERIMENTAL; Interventions: Device: Foley catheter | Arm Label: Group B (control group); Type: ACTIVE_COMPARATOR; Interventions: Device: Foley catheter | Intervention Type: DEVICE; Name: Foley catheter; Assigned to Arm(s): Group A (treatment group), Group B (control group)
D: Arm Label: Tamsulosin 0.4mg; Type: EXPERIMENTAL; Interventions: Drug: tamsulosin 0.4mg | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: No medication | Intervention Type: DRUG; Name: tamsulosin 0.4mg; Assigned to Arm(s): Tamsulosin 0.4mg | Intervention Type: OTHER; Name: No medication; Assigned to Arm(s): Control

Answer: D